CHEST Lisa G. Wood, PhD; Heather Powell, MMedSci; Terry Grissell, BSc; Thuy T.D. Nguyen, MD; Darren Shafren, PhD; Michael Hensley, MBBS; and Peter G. Gibson, MBBS 40 ( ) 4 6 wk (n = 26) 15% FEV 1 ( %FEV 1 ) 10 (25%) 30 (75%) ( %FEV 1 15%) (P =0.019) (P = 0.005) (P = 0.004 3) (airway inflammation); (virus) (airway obstruction); (asthma exacerbation); ACQ = asthma control questionnaire; CCQ = common cold questionnaire; ECP = eosinophilic cationic protein; EV = enterovirus; %FEV 1 = change in FEV 1 percent predicted; ICS = inhaled corticosteroid; IL = interleukin; IQR = interquartile range; MPV = metapneumovirus; PCR = polymerase chain reaction; PEF = peak expiratory flow; RSV = respiratory syncytial virus; RV = rhinovirus 696
COPD [1] 81% [2] Pizzichini [10] (IL) -5 (n =6) (n =2) [3 5] FEV 1 ( [2 6 10] 73% 93%) RANTES ( T ) ( 53% 20%) El-Radhi [18] IL-10 IL-5 CD25 [11] (ECP) Corne [12] (RV) 35 d 7d Chang [13] 89% [14] (PEF) [15] RV 2001 2 2005 5 PEF COPD John Hunter [11] [9 19 20] 25% 5wk PEF [16,17] 7 FEV 1 40% 4 6 wk From the School of Medicine and Public Health (Drs. Wood, Nguyen, Hensley, and Gibson, Ms. Powell, and Mr. Grissell), University of Newcastle, Newcastle, NSW, Australia; and Picornaviral Research Unit (Dr. Shafren), Royal Newcastle Hospital, Newcastle, NSW, Australia. This study was funded by a National Health and Medical Research Council of Australia Project Grant. Correspondence to: Lisa Wood, PhD, Hunter Medical Research Institute, Respiratory and Sleep Medicine, Level 3, HMRI, John Hunter Hospital, Newcastle, NSW 2305, Australia; e-mail:lisa. wood@newcastle.edu.au / (CCQ) [21] (ACQ) [22] ACQ ( β 2 - ) 7 0.75 [22] 1.50 www.chestjournal.org.cn CHEST 2007 11 4 11 697
[30] FEV 1 ) PCR ( %FEV 1 ) 15% RV EV RSV MPV PCR %FEV 1 15% PCR PCR (TaqMan Applied Biosystems) 12.5% [23] 4wk DNA (RealMasterMix Probe ROX John Hunter kit Eppendorf AG Hamburg Germany) 95 2 min PCR Hunter (HotMaster Taq DNA PCR Eppendorf AG) 40 95 15 s 60 1 min (ABI 7500 cycler Applied Biosystems Foster City CA) ( PCR PCR ) (1) ( ) (Buffer RLT Qiagen Hilden Germany) ( PCR PCR ) RNA RNA (PCR) (2) (HEL HEp-2) (3) 1 2 FEV 1 (L) ( 15% 15%) (May- Grnwald ) 400 (Stata version 7 Stata Corporation College [24 25] Station TX) (IQR) (Buffer RLT Qiagen) (%) Kruskal-Wallis (RNeasy kit Qiagen) Fisher χ 2 (P 0.05) RNA Kruskal-Wallis (Kruskal-Wallis 2 (Superscript II RT kit test Stata Corporation) Invitrogen Carlsbad CA) RNA 1 2 DNA Wilcoxon RV (EV) A B (RSV) 40 A B RV 30 (75%) EV 17 (42.5%) [11] (MPV) RNA PCR A 4 (10%) B 1 (2.5%) PCR (Taq-Man RSV 1 (2.5%) 11 2 1 probe Applied Biosystems Foster City CA) 3 10 (RV [26] EV [27] RSV A B [28] MPV [29] (25%) 30 698
1 (1) P (n = 26) (n = 30) (n =10) / 13.0 (9.4 43.0) 10.9 (9.3 16.8) 15.6 (11.4 50.5) 0.137 0.103 (2) 12 14 1 14 16 9 20 (76.9) 24 (88.9) 9 (90) 0.521 (2) / 7.2 (5.5 10.2) 7.06 (3.6 12.1) 14.1 (8.0 33.5) 0.054 (3) ICS / µg d -1(3) 650 (400 1 000) 650 (400 1 000) 2 000 (2 000 2 000) (4) 0.042 (3) (1) (2) (3) (4) (IQR) (%) Fisher Kruskal-Wallis P 0.008 (75%) 1 ACQ (ICS) 1 ( 2A) 2 ( 2B) ( 4) ( 3 1) %FEV 1 FEV 1 FEV 1 CCQ ACQ 2 CCQ 1/4 2 (1) P 10 (33.3) 30 2 (20.0) 10 0.693 (2) 0 3 0 0 1 0 20 7 0.333 (2) 4(20.0) 0 4 (20.0) 3 (42.9) 12 (60.0) 4 (57.1) /d 2(1 3) 30 2 (1 4) 10 0.962 (3) (1) (2) (3) (IQR) (%) Fisher Wilcoxon www.chestjournal.org.cn CHEST 2007 11 4 11 699
4 6 wk 3 (1) 1 2 1 2 P 1 2 P FEV 1 L 1.34 (2) 2.03 (2) 0.001 1.72 1.75 (2) 0.919 2.15 (1.06 1.56) (1.52 2.49) (1.22 1.95) (1.40 1.88) (1.70 2.94) % 61.50 (2) 89.24 0.001 72.50 (2) 69.43 (2) 0.799 90.00 (43.00 66.40) (81.70 92.86) (64.00 84.00) (68.18 78.33) (81.00 103.00) CCQ (3) 7.50 3.00 0.002 14.50 (2) 3.00 0.075 2.00 (4.50 12.50) (1.00 6.00) (3.0 19. 0) (0.00 11.00) (0.00 9.00) 0.5 0 0.061 2.5 0 0.041 0 (0 2.5) (0 1) (0 6) (0 0) (0 0) 3 2 0.039 4.5 1.5 0.399 0 (1.5 4) (0 3) (0 7) (0 4.5) (0 2) 1 0 0.002 2 0 0.028 0 (0 2) (0 1) (0 3) (0 0) (0 1) 2 0 0.001 4 2 0.024 1 (1 4) (0 1) (2 6) (1 2) (0 2) ACQ 2.29 (2) 0.57 0.001 2.79 (2) 1.57 0.045 0.57 (1.43 3.43) (0.29 1.71) (1.43 3.86) (0.86 2.43) (0.14 1.0) 2 0 0.001 2.5 0.5 0.018 0 (0.5 4) (0 1) (2 5) (0 2) (0 0) 2 0 0.001 1.5 0.5 0.123 0 (0 3) (0 1) (0 3) (0 2) (0 2) 2 0 0.001 2.5 2 0.122 0 (0 3) (0 2) (1 5) (0 3) (0 0) 2 0 0.001 3 2 0.489 1 (1 4) (0 1) (0 4) (0 3) (0 1) 1wk 2 0 0.001 2.5 2 0.502 0 (1 3.5) (0 2) (1 4) (0 4) (0 1) 2-3 1 0.001 3.5 2 0.058 1 (1 4) (0 2) (3 5) (0 3) (0 2) FEV 1 /% 4 2 0.001 3 3 0.752 1 (4 6) (1 2) (2 4) (2 4) (0 2) (1) (2) (IQR) P 0.05 (3) 5 700
90 60 30 0 1 P < 0.001 P = 0.075 NS P < 0.001 P = 0.045 P = 0.002 FEV 1 /L ACQ CCQ 1 P 1 2 NS 25% 5wk Seemungal [16] 2 COPD [17] (FEV 1 ) / 10 4 ml -1 / 10 6 ml -1 0 ICS 2 ( 1) (A) (B) [16] COPD Kruskal-Wallis 2 0 [17] FEV 1 ( 2) 3 CCQ 6 A 4 6 wk P = 0.019 (CCQ )( 1) 3 4 1.5 [31] ACQ 2 2 (ACQ 0.75) (ACQ 1.5) [31] 300 B P = 0.005 (FEV 1 ) 200 %FEV 1 ( 1 3) 100 www.chestjournal.org.cn CHEST 2007 11 4 11 701
4 (1) 1 2 1 2 P 1 2 P / 10 6 ml -1 5.36 (2) 4.37 0.600 2.16 2.03 0.273 1.94 (2.70 15.17) (1.89 4.95) (0.54 8.64) (0.72 4.41) (1.70 3.24) / 10 4 ml -1 265.32 (2) 127.80 0.023 85.06 85.66 0.655 16.22 (107.07 872.73) (66.69 182.22) (27.72 220.81) (5.47 181.94) (6.17 70.3) / 10 4 ml -1 1.74 6.12 0.182 0.00 3.44 0.180 2.67 (0.00 16.48) (1.04 46.58) (0.00 1.94) (0.00 7.04) (0.00 31.4) / 10 4 ml -1 162.23 140.13 0.938 44.50 105.40 0.655 166.85 (114.75 306.00) (78.22 389.78) (4.14 303.06) (62.10 243.90) (106.88 251.42) / 10 4 ml -1 3.01 1.47 0.906 0.00 2.88 0.180 2.54 (0.88 6.75) (0.00 11.17) (0.00 8.10) (1.15 5.33) (1.46 4.94) / 10 4 ml -1 5.24 3.08 0.224 4.42 3.40 0.180 5.03 (0.00 12.05) (0.00 3.43) (0.28 9.97) (1.00 5.44) (2.39 6.71) (1) (2) (IQR) P 0.05 [37] ( 2) ( 4) IL-8 ECP [38] [11] [39] [40] ( 2) [41 42] ( 4) ICS ( 1) ICS 3 2 [32] -α IL-1 [33] IL-6 4 6 wk 1/4 ECP [34] C4 [35 36] M 2 (25%) 702
17 Donaldson GC, et al. Eur Respir J 2003;22:931 936 18 El-Radhi AS, et al. Arch Dis Child 2000;83:158 162 1 Wark PA, et al. Thorax 2006;61:909 915 2 Wark PA, et al. Eur Respir J 2002;19:68 75 3 De Monchy JG, et al. Am Rev Respir Dis 1985;131:373 376 4 Wark PAB, et al. Clin Exp Allergy 2002;32:1750 1756 5 Gauvreau GM, et al. Am J Respir Crit Care Med 1999;160: 640 647 6 Busse WW, et al. Agents Actions Suppl 1989;28:41 56 7 Teran LM, et al. Am J Respir Crit Care Med 1997;155:1362 1366 8 Norzila MZ, et al. Am J Respir Crit Care Med 2000;161:769 774 9 Twaddell SH, et al. Eur Respir J 1996;9:2104 2108 10 Pizzichini MM, et al. Am J Respir Crit Care Med 1998;158: 1178 1184 11 Grissell TV, et al. Am J Respir Crit Care Med 2005;172:433 439 12 Corne JM, et al. Lancet 2002;359:831 834 13 Chang KC, et al. Chest 2000;117:944 949 14 Coyle YM, et al. Int J Qual Health Care 2002;14:69 75 15 Ferreira A, et al. Respiration 2002;69:136 142 16 Seemungal TAR, et al. Am J Respir Crit Care Med 2000;161: 1608 1613 19 Gibson PG, et al. Am J Respir Crit Care Med 1998;158:36 41 20 Wark PAB, et al. Clin Exp Allergy 2001;31:1745 1753 21 Nicholson KG, et al. BMJ 1993;307:982 986 22 Juniper EF, et al. Eur Respir J 1999;14:902 907 23 American Thoracic Society. Am Rev Respir Dis 1987; 136: 1285 1298 24 Wark PA, et al. Clin Exp Allergy 2001;31:1745 1753 25 Cai Y, et al. Eur Respir J 1998;11:848 853 26 Deffernez C, et al. J Clin Microbiol 2004;42:3212 3218 27 Nijhuis M, et al. J Clin Microbiol 2002;40:3666 3670 28 van Elden LJ, et al. J Clin Microbiol 2003;41:4378 4381 29 Maertzdorf J, et al. J Clin Microbiol 2004;42:981 986 30 van Elden LJ, et al. J Infect Dis 2004;189:652 657 31 Juniper EF, et al. Respir Med 2006;100:616 621 32 Noah TL, et al. Immunopharmacology 1998;39:193 199 33 Schleimer RP. Proc Am Thorac Soc 2005;2:342 346 34 Dimova-Yaneva D, et al. Clin Exp Allergy 2004;34:555 558 35 Kimpen JLL, et al. Pediatr Res 1992;32:160 164 36 Gentile DA, et al. Ann Allergy Asthma Immunol 2003;91: 270 274 37 Jacoby DB, et al. J Allergy Clin Immunol 2001;107:211 218 38 Greiff L, et al. Eur Respir J 1999;13:41 47 39 Greiff L, et al. Clin Physiol Funct Imaging 2003;23 40 Skoner DP, et al. Ann Allergy Asthma Immunol 2001;87:303 306 41 Londhe V, et al. FEBS Lett 2003;553:33 38 42 Hashimoto K, et al. Am J Respir Crit Care Med 2004;170: 306 312 CHEST 2007;131:415 423 www.chestjournal.org.cn CHEST 2007 11 4 11 703